Raymond James analyst Rick Paterson downgrades FIGS (NYSE:FIGS) from Strong Buy to Outperform and lowers the price target from $12 to $8.
Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial
Regenxbio Inc (NASDAQ:RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic…